Lyu J, et al. - In this retrospective case series study, researchers reported the clinical characteristics of preterm infants with type 1 retinopathy of prematurity (ROP) at postmenstrual age (PMA) of > 40 weeks and compared the treatment results of intravitreal ranibizumab (IVR) and laser therapy. For this investigation, they included 27 eyes of 14 infants, primarily treated for type 1 ROP after 40 weeks PMA by IVR (17 eyes in 9 infants) or by laser photocoagulation (10 eyes in 5 infants). According to findings, PMA showed enhanced fibrotic proliferation in preterm infants with type 1 ROP at > 40 weeks. ROP regression is effectively promoted by both primary IVR and laser. Primary IVR cannot guarantee complete retinal vascularization, but the risk of fibrotic contraction is associated with it.